Market Place
Sourcing Support
Nippon Shinyaku & Atsena Partner on ATSN-101 in U.S. & Japan
13 Nov 2024 //
GLOBENEWSWIRE
Atsena To Present ATSN-201 Data At AAO 2024 Annual Meeting
10 Oct 2024 //
GLOBENEWSWIRE
Atsena Therapeutics to Present at Chardan’s Genetic Medicines Conference
24 Sep 2024 //
GLOBENEWSWIRE
Atsena Therapeutics Receives Orphan Drug Designation for ATSN-201
17 Sep 2024 //
GLOBENEWSWIRE
Atsena Therapeutics Announces 12-Month Phase I/II Trial Data
05 Sep 2024 //
GLOBENEWSWIRE
Atsena Therapeutics Gets FDA Rare Pediatric Disease Designation For ATSN-201
14 Aug 2024 //
GLOBENEWSWIRE
Atsena: Positive ATSN-201 Gene Therapy Data In XLRS Trial Phase I/II
01 May 2024 //
GLOBENEWSWIRE
Atsena Announces Initiation of Dosing in Phase I/II Trial Evaluating ATSN-201
13 Mar 2024 //
GLOBENEWSWIRE
Atsena Receives Rare Pediatric Disease Designation from FDA for ATSN-101
16 Jan 2024 //
GLOBENEWSWIRE
Atsena Announces Positive 12-month Safety Data from Phase I/II of ATSN-101
04 Dec 2023 //
GLOBENEWSWIRE
Atsena Therapeutics Receives FDA RMAT Designation for ATSN-101
14 Nov 2023 //
GLOBENEWSWIRE
Atsena downsizes to funnel money toward new capsid program
05 Oct 2023 //
FIERCE BIOTECH
Atsena Announces First Patient Dosed in Ph I/II Clinical Trial of ATSN-201
28 Aug 2023 //
GLOBENEWSWIRE
Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201
01 May 2023 //
GLOBENEWSWIRE
Atsena Therapeutics Announces Positive 6-month from Ongoing Ph I/II Clinical
25 Apr 2023 //
GLOBENEWSWIRE
Atsena Announces Six-Month Data from Phase I/II Clinical Trial of ATSN-101
11 Apr 2023 //
GLOBENEWSWIRE
Atsena to Present Positive Data from the Phase I/II Clinical Trial of ATSN-101
08 Feb 2023 //
GLOBENEWSWIRE
Atsena to Present at NewYorkBIO’s December 2022 Emerging Life Science
07 Dec 2022 //
GLOBENEWSWIRE
Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial
03 Oct 2022 //
GLOBENEWSWIRE
Atsena Therapeutics Announces Late-Breaker Presentation at Ophthalmology 2022
21 Sep 2022 //
GLOBENEWSWIRE
Atsena Therapeutics Announces Opening of New Office and Laboratory Space
27 Jul 2022 //
GLOBENEWSWIRE
Atsena Therapeutics Announces Presentations at ARVO and ASGCT
02 May 2022 //
GLOBENEWSWIRE
Atsena Therapeutics Unveils XLRS Gene Therapy Program Leveraging Novel Capsids
18 Oct 2021 //
GLOBENEWSWIRE
Atsena Therapeutics Appoints Linda B. Couto, PhD, as Chief Scientific Officer
16 Aug 2021 //
GLOBENEWSWIRE
Atsena Therapeutics Appoints Jennifer Wellman to Board of Directors
12 Jul 2021 //
GLOBENEWSWIRE
Atsena Therapeutics Receives Orphan Drug Designation from the FDA
28 Jun 2021 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.